Back to search results

Magnesium Sulfate and Neuromonitoring During Surgery

This study is looking at how a common medication, Magnesium Sulfate, affects brain and nerve monitoring during certain surgeries. Magnesium Sulfate is often used to help with pain after surgery. During complex spine or brain surgeries, doctors use intraoperative neuromonitoring (IONM) to check nerve function and prevent damage. We don't yet know how Magnesium Sulfate affects these monitoring signals. This study will give some patients Magnesium Sulfate and others a saline solution (salt water) to see if there are changes in the nerve signals. We'll measure changes in signals called SSEPs (somatosensory evoked potentials) up to 30 minutes after the medication is given. You might be able to join if you are between 18 and 80 years old, in good health, and having spine or brain surgery that requires nerve monitoring. The study is currently recruiting 50 participants, but its overall status is unclear.

Study design
This is a prospective, double-blind, randomized, placebo-controlled study involving 50 participants. This means participants will be randomly assigned to receive either Magnesium Sulfate or a saline solution, and neither you nor your doctors will know which you are receiving.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, changes in SSEP amplitude, will be measured up to 30 minutes after the study medication is given.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04938765

Effect of Magnesium Sulfate Bolus on Intraoperative Neuromonitoring

Recruiting
PHASE4Ages 18–80InterventionalDiagnostic
Loma Linda University
~50 participants
Updated 2026-04-24 on ClinicalTrials.gov
What's tested:Magnesium sulfateNormal Saline

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in the amplitude of SSEPs.
Measured over Up to 30 minutes after the end of bolus dose of MgSO4 or Normal saline.

Conditions

Intraoperative Neurophysiological Monitoring
Magnesium Sulfate

Explore related trials

Cranial Base SurgerySpine Surgery

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Rashmi Vandse, MD · PRINCIPAL_INVESTIGATOR · Loma Linda University

Who to contact

Rashmi Vandse, MD
[email protected]
9095584000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients aged 18 to 80 years
Belonging to American Society of Anesthesiologists physical status (ASA) I, II
Undergoing elective spine or cranial surgery where intraoperative neuromonitoring including short latency somatosensory evoked potentials (SSEP or SEP) and transcranial electrical muscle motor evoked potentials recording from muscles (TceMEP or TcMEP or mMEP or MEP) is planned.

Exclusion

Magnesium use within the last 2 days, either intravenous or oral supplements.
Patients with known electrolyte imbalances (Sodium \<135 or \>145 mmol/L OR Potassium \< 3.5 or \> 5.0 mmol/L, Magnesium \>1.2 mmol/L.
Severe cardiac or cardiac conduction disorders.
Severe pulmonary disease.
Patients with significant neuromuscular disorders or preexisting motor or sensory deficits other than focal upper limb neuropathy or focal cervical radiculopathy or mild cervical myelopathy.
Severe Renal disease - serum creatinine of \> 2 mg/dl.
Pregnant or breastfeeding patients.
Unable to obtain adequate baseline SSEPs and MEPs.

What this trial measures

  • Change in the amplitude of SSEPs.Up to 30 minutes after the end of bolus dose of MgSO4 or Normal saline.

    Baseline SSEP recording is done before the administration of MgSo4 or placebo and will be compared with the SSEPs measured at 0,10 and 30 minutes following the end of the bolus dose of MgSO4 or normal saline. Any change in the amplitude will be analyzed. For SSEPs, 50% reduction in amplitude will be considered as significant change.